Abstract:Drug-induced liver injury (DILI) is a common clinical pharmacogenic disease. In the United States and Europe, DILI is the most common cause of acute liver failure. Drugs can cause hepatic damage either directly through inherent hepatotoxic properties or indirectly by inducing oxidative stress, immune responses, and inflammatory processes. These pathways can culminate in hepatocyte necrosis. The role of the gut microecology in human health and diseases is well recognized. Recent studies have revealed that the imbalance in the gut microecology is closely related to the occurrence and development of DILI. The gut microecology plays an important role in liver injury caused by different drugs. Recent research has revealed significant changes in the composition, relative abundance, and distribution of gut microbiota in both patients and animal models with DILI. Imbalance in the gut microecology causes intestinal barrier destruction and microorganism translocation; the alteration in microbial metabolites may initiate or aggravate DILI, and regulation and control of intestinal microbiota can effectively mitigate drug-induced liver injury. In this paper, we provide an overview on the present knowledge of the mechanisms by which DILI occurs, the common drugs that cause DILI, the gut microbiota and gut barrier composition, and the effects of the gut microbiota and gut barrier on DILI, emphasizing the contribution of the gut microecology to DILI.
What problem does this paper attempt to address?
The problems that this paper attempts to solve are the pathogenesis of drug - induced liver injury (DILI) and its relationship with the gut microbiota, and to explore emerging treatment strategies. Specifically, the paper focuses on the following aspects:
1. **Pathogenesis of DILI**: It discusses the mechanisms of DILI occurrence, including direct hepatotoxicity, idiosyncratic hepatotoxicity and indirect hepatotoxicity. These mechanisms involve direct damage to liver cells by drugs or their metabolites, as well as liver injury indirectly caused by immune responses and inflammatory processes.
2. **Common drugs causing DILI**: It lists various types of drugs that may cause DILI, such as non - steroidal anti - inflammatory drugs, Chinese herbal medicines and dietary supplements, anti - tuberculosis drugs, antifungal drugs, antibiotics, central nervous system drugs, etc., and analyzes their potential mechanisms.
3. **Role of gut microbiota and gut barrier**: It discusses the composition of the gut microbiota and its role in health and disease, especially its impact on DILI. The paper points out that in DILI patients, the diversity of the gut microbiota is reduced, the relative abundance of beneficial bacteria is decreased, and the potentially pathogenic bacteria are increased. These changes may lead to impaired gut barrier function, which in turn may trigger or exacerbate DILI.
4. **Impact of gut microbiota on DILI**: It analyzes in detail the role of the gut microbiota in liver injury caused by specific drugs (such as acetaminophen, APAP). For example, probiotics such as Akkermansia muciniphila and Bacteroides vulgatus can alleviate APAP - induced liver injury, while some antibiotics (such as vancomycin) may exacerbate liver injury by changing the composition of the gut microbiota.
5. **Emerging treatment strategies**: It explores potential methods for preventing and treating DILI by modulating the gut microbiota, including the use of probiotics, prebiotics and other microbial intervention means.
In conclusion, this paper aims to comprehensively understand the pathogenesis of DILI, especially the role of gut microbiota in it, and propose new treatment strategies to improve the clinical management of DILI.